ConductScience.org, home
MDA-MB-468
API referenceFor AI assistants

Cell line · CVCL_0419

Papers290

1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.

1 to 20 of 290

Download this page as JSON
PaperJournalYearHow we knowRetractedSource
Comprehensive characterization of the cellular and molecular consequences of LCN2 loss in MDA-MB-231 triple-negative breast cancer cellsFront Cell Dev Biol2026Its Methods give the RRID and name the linePubMed
Overcoming platinum resistance by the disulfiram metabolite CuET in novel preclinical models of human carcinomas.Mol Oncol2026Its Methods give the RRID and name the linePubMed
ESR1 mutations are associated with enhanced MTORC1 signaling in a context-dependent manner.Commun Biol2026Its Methods give the RRID and name the linePubMed
Lysyl oxidase inhibition disrupts mitochondrial homeostasis to create vulnerability to ferroptosis in TNBC.Cell Rep Med2026Its Methods give the RRID and name the linePubMed
CRB-701: A Second-generation Nectin-4-Targeted Antibody-Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors.Cancer Res Commun2026Its Methods give the RRID and name the linePubMed
Role of orphan G protein-coupled receptor GPR52 in breast cancer cell multicellular organization and collective invasion.Br J Cancer2026Its Methods give the RRID and name the linePubMed
HSPA8 globally modulates transcriptome profile and PI3K/AKT signaling pathway to facilitate malignant progression phenotypes of triple-negative breast cancer.Sci Prog2026Its Methods give the RRID and name the linePubMed
Meditope-Enabled Chimeric Antigen Receptors Facilitate Plug-and-Play Control of T Cells.Cancer Immunol Res2026Its Methods give the RRID and name the linePubMed
An antibody-PROTAC conjugate targets BRD4/c-Myc/PD-L1 to enhance immunotherapy efficacy in triple-negative breast cancer.Cell Rep Med2026Its Methods give the RRID and name the linePubMed
Broad-Spectrum Antibiotics Attenuate the Chemotherapeutic Efficacy of Doxorubicin in MDA-MB-468 Breast Cancer Cells.Int J Breast Cancer2026Its Methods give the RRID and name the linePubMed
Phosphoproteomic Profiling Identifies PAK4 S474 Phosphorylation Affects Docetaxel Chemosensitivity via Modulation of Microtubule Stabilization in Breast Cancer.Biomedicines2026Its Methods give the RRID and name the linePubMed
Intratumoral Hypoxia Triggers Mitochondrial BHLHE40 ROS Sensing Pathway to Promote Radioresistance in Triple-Negative Breast Cancer.Adv Sci (Weinh)2026Its Methods give the RRID and name the linePubMed
Combine antibody-drug conjugate with cmLumiOpto for triple-negative breast cancer treatment.Cell Rep Med2026Its Methods give the RRID and name the linePubMed
Immune-associated alternative splicing signatures define molecular subtypes in breast cancer.iScience2026Its Methods give the RRID and name the linePubMed
LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor Combinations.Mol Cancer Ther2026Its Methods give the RRID and name the linePubMed
Design optimization of antibody-ligand motifs to enhance CAR-T redirection activity against solid tumors.Cell Rep Med2026Its Methods give the RRID and name the linePubMed
The WEE1 inhibitor azenosertib broadly enhances efficacy of antibody-drug conjugates with topoisomerase I and microtubule inhibitor payloads.iScience2026Its Methods give the RRID and name the linePubMed
Tumor-educated macrophages promote cytokine-driven lung colonization in triple-negative breast cancer.Oncoimmunology2026Its Methods give the RRID and name the linePubMed
P2RY6+ tumor-associated macrophages as a therapeutic target: suppressing tumor growth and enhancing chemosensitivity in triple-negative breast cancer.Cell Oncol (Dordr)2026Its Methods give the RRID and name the linePubMed
Modeling the role of urokinase-type plasminogen activator, uPA, and circulating cancer-associated fibroblasts (cCAFs) in breast cancer cell extravasation.Clin Exp Metastasis2026Its Methods give the RRID and name the linePubMed

cell-lines-2026-11-14-0.1.0

Next page

Sources 4

  • CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
  • PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
  • NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
  • PubMedNLM's terms
Each source's terms
  • CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
  • PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
  • NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
  • PubMedNLM's terms

Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/cell-lines/v1/CVCL_0419/papers

API referenceFor AI assistants